After being approved as a supplier to some of the world’s largest pharma companies, Medicollect is proud of also having completed vendor qualification in one of the largest CROs, Medpace.
Medpace has operations in over 50 countries and holds a strong position in diabetes trials. Therefore Medicollect and Medpace match exceptionally well.
Medpace has already asked Medicollect to provide participants for a study on the treatment of diabetic foot ulcers in both the UK and Denmark. We expect a lot from the cooperation with Medpace “says Rene Ludwig, CEO of Medicollect.
Copenhagen, Denmark – Medicollect today announced its expansion into UK, increasing its acceptance footprint across the continent. The addition of the British network extends the company’s reach to 3, 4 million diabetes patients.
According to a report produced for the drug company Novartis clinical trials in the United Kingdom cost significantly more than in other European countries, in large because of poor rates of recruitment (source).
“This means that there is an increasing need for innovative and reliable solutions that address market needs,” says Torben Lind, COO at Medicollect. “Our investment in UK will secure that test patients for clinical diabetes trials in United Kingdom will be provided at the same fast, safe and reliable way that Medicollect has serviced the Scandinavian market.
Through collaborating with diabetes stakeholders in UK and Denmark, Medicollect is directly contributing to bringing medical innovation to patients faster and support United Kingdom’s transformation to once more being a strong center for clinical trials.
Want to know more?
Contact Torben Lind
There has been great interest in participating in Medicollect’s diabetic panel in Denmark. Therefore Medicollect has decided to establish a panel in England.
In UK the panel will be called “My Life With Diabetes” and the goal is to reach 50,000 British members during 2016.
“It’s clearly a very ambitious goal, but we have set the goal high because our clients demand far more patients in England than in Denmark,” says director Henrik Vincentz.
So far, companies such as SANOFI, NOVO and GSK have shown interest in using Medicollect’s services in UK.